Device Trial Radar · NCT02748018
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
959
Actual
Start
May 25, 2017
Primary completion
Nov 1, 2023
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Apr 22, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
Conditions
- Type 1 Diabetes
Interventions
670G and 770G Insulin PumpDevice
Medtronic 670G and 770G Hybrid Closed Loop Systems
Subject's Current Diabetes TherapyDevice
Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
Primary outcomes
What the sponsor says the trial is designed to measure.
- CSII Cohort: Baseline A1C > 8%: Change in A1C (∆A1C)Time frame: Baseline and end of 6-month study period
- CSII Cohort: Baseline A1C ≤ 8%: Time in Hypoglycemic RangeTime frame: 6 months study period
- MDI Cohort: Baseline A1C > 8%: Change of A1C (∆A1C)Time frame: Baseline and end of 6-month study period
3 more outcomes with a free account
Locations
36 sites in 9 countries. Site status is shown where the registry gives one.
Scripps Health System
La Jolla, California
Stanford University
Palo Alto, California
Center of Excellence in Diabetes & Endocrinology
Sacramento, California
33 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.